Pelvic Pain Education and Skills Training for Women Veterans

Sponsor
Baylor College of Medicine (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06062043
Collaborator
US Department of Veterans Affairs (U.S. Fed)
20
1
2
12
1.7

Study Details

Study Description

Brief Summary

The goals of this pilot randomized clinical trial are three-fold: 1) to test the feasibility of conducting a larger randomized trial using a brief Acceptance and Commitment Training (ACT) group intervention for women veterans with pelvic pain compared to usual care; 2) assess treatment acceptability by women veterans, and 3) identify appropriate pain-related treatment outcomes for the larger randomized trial.

Participants will be randomly assigned to participate in either the ACT condition or treatment as usual condition, complete three surveys (before, after, and 3-months after first survey), and complete a phone interview (if assigned to the ACT condition).

Researchers will compare the ACT condition and treatment as usual condition to see if there are meaningful differences in health outcomes. Due to the small sample size and pilot nature of this study, significance testing will not be performed.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Brief ACT with CPP Education Treatment
N/A

Detailed Description

Chronic pelvic pain (CPP) is a debilitating pain condition that disproportionately affects women veterans (30% vs. 16% of nonveteran women vs. 3% of men). Pain intensity and disability are further exacerbated by psychosocial factors (such as depression, anxiety, posttraumatic distress) that may not be fully addressed through pharmacological and surgical interventions. Cognitive and behavioral therapies, such as Acceptance and Commitment Therapy (ACT), are identified as first-line nondrug treatments for pain conditions. Given the multifactorial nature of CPP, ACT may be of particular benefit to these patients as it provides a unified (transdiagnostic) approach to the treatment of co-occurring disorders, such as chronic pain, depression, and anxiety. Specifically, ACT targets core psychological and behavioral factors (e.g., avoidance) that underlie many psychiatric and medical conditions. Several meta-analyses show ACT is effective, even when compared to active interventions such as Cognitive-Behavioral Therapy.

In this pilot study, researchers will examine the feasibility and acceptability of conducting a larger randomized controlled trial to establish the efficacy of a brief ACT group treatment for women veterans experiencing pelvic pain. This pilot study builds on previous work adapting an empirically supported one-day ACT workshop to the specific needs of women veterans based on their feedback.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
20 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Outcomes Assessor)
Masking Description:
Participants and outcomes assessors will be blinded to randomization assignments.
Primary Purpose:
Treatment
Official Title:
Pelvic Pain Education and Skills Training for Women Veterans - Pilot Study
Anticipated Study Start Date :
Oct 1, 2023
Anticipated Primary Completion Date :
Jul 30, 2024
Anticipated Study Completion Date :
Sep 30, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Brief ACT with CPP Education Group

The Brief Acceptance and Commitment Training (ACT) with Chronic Pelvic Pain (CPP) education Group will attend weekly 90-minute sessions for up to six weeks to learn new ways to respond to their pain and engage in meaningful activities.

Behavioral: Brief ACT with CPP Education Treatment
The Brief ACT with CPP Education treatment provides women veterans with new ways of responding to difficult thoughts and emotions related to pain while also encouraging them to engage in meaningful life activities. The CPP educational component includes information about pathology, risk factors, health outcomes, and treatment that are specific to women's biological and reproductive functioning. Treatment content has been further tailored to reflect the cultural experiences of women veterans (including discussions on the interplay between military culture, perceived social norms, and gender role expectations).
Other Names:
  • Brief ACT for Pelvic Pain
  • No Intervention: Enhanced Treatment as Usual

    The enhanced treatment as usual (TAU) condition will receive a letter with CPP-specific treatment resources and encouraged to consult with their VHA primary care clinicians for additional education and treatment options.

    Outcome Measures

    Primary Outcome Measures

    1. Feasibility of recruitment [Up to 1 year]

      Recruitment rates (number of women veterans enrolled/number who complete treatment)

    2. Acceptability of intervention [3-month follow-up]

      Qualitative interview inquiring about how satisfactory women veterans found the intervention (such as likes, dislikes, and suggestions for improvement)

    3. Client Satisfaction Questionnaire (CSQ-8) [up to 8-weeks from baseline]

      The 8 item CSQ-8 measures patient satisfaction with services rendered. Scores range from 8 to 32. Higher scores indicate greater satisfaction.

    Secondary Outcome Measures

    1. Mean change score in Pelvic Floor Distress Inventory (PFDI-20) [Change at 3-month follow-up from baseline]

      The 20 item PFDI-20 measures emotional distress related to pelvic pain symptoms. Scores range from 0-300. Higher scores indicate greater pelvic pain-related distress.

    2. Mean change score in Brief Pain Inventory (BPI-SF), Pain Interference Scale [Change at 3-month follow-up from baseline]

      The 7 item BPI-SF, Pain Interference Scale measures level of pain interference in daily activities. Items are averaged to compute a mean scale score that ranges from 0 to 10. Higher scores indicate greater interference with daily activities.

    3. Mean change in Numeric Rating Scale (NRS) [Change at 3-month follow-up from baseline]

      This single item will measure worst pain severity in past 7 days. Scores range from 0-10. Higher scores indicate greater pain severity.

    Other Outcome Measures

    1. Mean change in Chronic Pain Acceptance Questionnaire (CPAQ-Revised) [Change at 3-month follow-up from baseline]

      The 20 item CPAQ-revised is designed to measure acceptance of pain, which is thought to reduce unsuccessful attempts to avoid or control pain and thus focus on engaging in valued activities and pursuing meaningful goals. Scores range from 0-120 with higher scores reflecting greater pain acceptance.

    2. Mean change in Chronic Pain Values Inventory (CPVI) [Change at 3-month follow-up from baseline]

      The 12 item CPVI measures which values are important to an individual and the degree of success they are having in following their values. Two average scores are created (mean success and mean discrepancy ratings) that range from 0-5. Higher mean scores reflect greater success or greater discrepancy between importance of value and success of achieving it.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Served in US Armed Forces

    • Self-identify as female/woman

    • Have a diagnosis of chronic pelvic pain (CPP)

    • Endorse moderate to severe pain (worst pain score ≥ 4 on Numeric Rating Scale [NRS]) AND pain-related distress (score ≥ 80 on Pelvic Floor Distress Inventory [PFDI-20])

    • Be stable on mood and pain medication for four weeks and not scheduled for medical tests or procedures that might influence pain-related outcomes (e.g., surgical interventions, nerve block treatments)

    Exclusion Criteria:
    • Cognitive impairment

    • Uncontrolled bipolar or psychotic diagnosis

    • Active suicidal or homicidal ideation

    • Receiving concurrent psychotherapy or who have received Acceptance and Commitment Therapy (ACT) within the past year

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Michael E. DeBakey VA Medical Center Houston Texas United States 77030

    Sponsors and Collaborators

    • Baylor College of Medicine
    • US Department of Veterans Affairs

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Derrecka Boykin, Principal Investigator, Baylor College of Medicine
    ClinicalTrials.gov Identifier:
    NCT06062043
    Other Study ID Numbers:
    • H-53941
    First Posted:
    Oct 2, 2023
    Last Update Posted:
    Oct 4, 2023
    Last Verified:
    Oct 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Derrecka Boykin, Principal Investigator, Baylor College of Medicine
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Oct 4, 2023